Trial reportTransactions of the American Ophthalmological Society2016
The Effect of Different Dosing Schedules of Intravitreal Sirolimus, a Mammalian Target of Rapamycin (mTOR) Inhibitor, in the Treatment of Non-Infectious Uveitis (An American Ophthalmological Society Thesis).
Trial report in Transactions of the American Ophthalmological Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Utilisation of composite endpoint outcome to assess efficacy of tocilizumab for non-infectious uveitis in the STOP-Uveitis Study.The British journal of ophthalmology · 2023Trial
- Noninfectious uveitis: Management with biologic agents.Indian journal of ophthalmology · 2026Review
- Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond.Frontiers in ophthalmology · 2024Review
- Cellular Recycling Gone Wrong: The Role of Dysregulated Autophagy and Hyperactive mTORC1 in the Pathogenesis of Sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023Article
- Systemic Administration of Acazicolcept, a Dual CD28 and Inducible T cell Costimulator Inhibitor, Ameliorates Experimental Autoimmune Uveitis.Translational vision science & technology · 2023Article
- Intraocular therapy in noninfectious uveitis.Journal of ophthalmic inflammation and infection · 2021Review
- Update on the Management of Uveitic Macular Edema.Journal of clinical medicine · 2021Review
- Refractory Sarcoidosis: A Review.Therapeutics and clinical risk management · 2020Review
- Dexamethasone Provides Effective Immunosuppression for Improved Survival of Retinal Organoids after Epiretinal Transplantation.Stem cells international · 2019Article
- In vivo and in vitro toxicity evaluation of liposome-encapsulated sirolimus.International journal of retina and vitreous · 2019Article
- Emerging therapies in the management of macular edema: a review.F1000Research · 2019Review
- Update in treatment of uveitic macular edema.Drug design, development and therapy · 2019Review
- Outcomes of treatment with sirolimus for non-infectious uveitis: a meta-analysis and systematic review.Clinical ophthalmology (Auckland, N.Z.) · 2019Review
- The Eyes Have it: A Rheumatologist's View of Uveitis.Arthritis & rheumatology (Hoboken, N.J.) · 2018Review
- A Review of the Landscape of Targeted Immunomodulatory Therapies for Non-Infectious Uveitis.Ophthalmology and therapy · 2018Review
- A Review of Systemic Biologics and Local Immunosuppressive Medications in Uveitis.Journal of ophthalmic & vision researchReview
- A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine if two different doses of intravitreal sirolimus, an mTOR inhibitor, can decrease inflammation and is safe in eyes with non-infectious posterior, intermediate, or panuveitis in the Sirolimus as a Therapeutic Approach UVEitis: Protocol-2 (SAVE-2) Study.
methodsSAVE-2 is a prospective randomized, phase II, open-label interventional clinical trial conducted at 4 clinical centers in the United States. Eligible subjects were randomized into one of two treatments. Group 1 received 440µg of intravitreal sirolimus in study eyes on days 0, 30, 60, 90, 120, and 150; group 2 received 880µg of intravitreal sirolimus on days 0, 60, and 120. Fellow eyes were also eligible to receive sirolimus (of opposite dose to that of study eye). Primary endpoint of the study was at month 6 (M6).
results24 subjects have been randomized in SAVE-2 and are included in the analysis. Vitreous haze decreased by ≥2 steps in 63.6% and 50% of patients in groups 1 and 2, respectively at M6 (p=0.695). Mean change in best-corrected visual acuity for subjects was +3.66 and -2.91 ETDRS letters in group 1 and 2, respectively. Among subjects with macular edema at baseline (n=13), the mean change in foveal thickness was -89.42µm in group 1 and +81.5µm in group 2 at M6.
conclusionsBoth low and high doses of intravitreal sirolimus were found to decrease vitreous haze in eyes with non-infectious uveitis. Low dose (440µg) sirolimus administered monthly may be more efficacious in reducing uveitic macular edema than high dose (880µg) administered every 2 months.
Indexed as
Identifiers
27630374PMC5012855W2534106669What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.